X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (11) 11
index medicus (8) 8
humans (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
colorectal cancer (6) 6
colorectal neoplasms - drug therapy (6) 6
folfiri (6) 6
hypertension (6) 6
camptothecin - administration & dosage (5) 5
camptothecin - analogs & derivatives (5) 5
cancer (5) 5
fluorouracil - administration & dosage (5) 5
leucovorin - administration & dosage (5) 5
metastatic colorectal cancer (5) 5
oncology (5) 5
oxaliplatin (5) 5
adult (4) 4
aged (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
chemotherapy (4) 4
colorectal neoplasms - mortality (4) 4
female (4) 4
folfiri-bevacizumab (4) 4
leucovorin (4) 4
male (4) 4
middle aged (4) 4
antibodies, monoclonal, humanized - administration & dosage (3) 3
bevacizumab - administration & dosage (3) 3
colorectal neoplasms - pathology (3) 3
colorectal neoplasms - secondary (3) 3
fluorouracil (3) 3
hypertension - chemically induced (3) 3
neoplasm metastasis (3) 3
pharmacology & pharmacy (3) 3
treatment outcome (3) 3
aged, 80 and over (2) 2
alleles (2) 2
angiogenesis (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
cetuximab (2) 2
cetuximab - administration & dosage (2) 2
clinical trials (2) 2
colorectal (2) 2
colorectal carcinoma (2) 2
colorectal neoplasms - genetics (2) 2
disease-free survival (2) 2
folfiri/bevacizumab (2) 2
genotype (2) 2
infusional fluorouracil (2) 2
metastases (2) 2
mfolfox6 (2) 2
plus bevacizumab (2) 2
plus irinotecan (2) 2
polymorphism (2) 2
predictive factor (2) 2
prognosis (2) 2
progression (2) 2
survival rate (2) 2
therapy (2) 2
toxicity (2) 2
trial (2) 2
大腸癌 (2) 2
1st-line treatment (1) 1
2nd-line treatment (1) 1
3' untranslated regions (1) 1
5' untranslated regions (1) 1
5-fluorouracil (1) 1
administering (1) 1
angiogenesis inhibitors - pharmacology (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
anti-cancer effect (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - economics (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antibodies, monoclonal, humanized - pharmacology (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - economics (1) 1
apoptosis (1) 1
arterial-hypertension (1) 1
asian continental ancestry group (1) 1
autophagy (1) 1
autophagy - genetics (1) 1
bevacizumab - adverse effects (1) 1
bevacizumab - economics (1) 1
bevacizumab plus mfolfox6 (1) 1
bevacizumab-associated toxicity (1) 1
bicc-c (1) 1
biologic agents (1) 1
biomarkers, tumor - genetics (1) 1
bladder invasion (1) 1
bleeding (1) 1
blood pressure (1) 1
blood pressure - drug effects (1) 1
blood-pressure (1) 1
breast-cancer (1) 1
camptothecin - adverse effects (1) 1
camptothecin - therapeutic use (1) 1
carcinoma (1) 1
cetuximab - economics (1) 1
chemotherapy, adjuvant (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 11, pp. 2780 - 2785
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 77, pp. 13 - 20
Abstract Purpose The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding and thromboembolism. To date, there is no biomarker... 
Hematology, Oncology and Palliative Medicine | Hypertension | Single-nucleotide polymorphism | Bevacizumab-associated toxicity | FOLFIRI/bevacizumab | Autophagy | Colorectal cancer | APOPTOSIS | INHIBITION | ONCOLOGY | SENESCENCE | STRESS | PLUS BEVACIZUMAB | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Middle Aged | Genotype | Male | Neoplasm Metastasis | Protein-Tyrosine Kinases - genetics | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Hypertension - chemically induced | Polymorphism, Single Nucleotide - genetics | Adult | Camptothecin - administration & dosage | Cetuximab - administration & dosage | Female | Aged | Autophagy - genetics | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Genetic aspects | Metastasis | Single nucleotide polymorphisms | Thromboembolism | Vascular endothelial growth factor | Medicine, Preventive | Preventive health services | Measurement | Endothelial growth factors | Blood pressure | Toxicity | Genes | Colorectal carcinoma | Clinical trials | Patients | Two phase | Bleeding | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Alleles | Phagocytosis | Genotypes | Polymorphism | Proteinuria | Cancer | Index Medicus
Journal Article
by Budai, B and Nagy, T and Lang, I and Hitre, E
ANGIOGENESIS, ISSN 0969-6970, 01/2013, Volume 16, Issue 1, pp. 113 - 121
The role of d,l-leucovorin (d,l-LV) dose on efficacy and toxicity of first-line bevacizumab+mFOLFIRI or mFOLFIRI treatment has never been investigated in... 
Hypertension | INFUSIONAL FLUOROURACIL | IRINOTECAN FOLFIRI | LEUCOVORIN | Leucovorin dose | mFOLFIRI | Colorectal cancer | Efficacy | FOLINIC ACID | BLOOD-PRESSURE | CHEMOTHERAPY | Bevacizumab | PHASE-II TRIAL | FOLFIRI-BEVACIZUMAB | ARTERIAL-HYPERTENSION | PERIPHERAL VASCULAR DISEASE | CARCINOMA
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 01/2012, Volume 22, Issue 1, pp. 69 - 72
The impact of thymidylate synthase (TYMS), methylenetetrahydrofolate reductase (MTHFR), and serine hydroxymethyltransferase 1 (SHMT1) gene polymorphisms and... 
first-line chemotherapy | survival | metastatic colorectal cancer | polymorphism | hypertension | SHMT1 C1420T | FOLFIRI+ bevacizumab | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Colorectal Neoplasms - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | INDEL Mutation | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Methylenetetrahydrofolate Reductase (NADPH2) - genetics | Colorectal Neoplasms - drug therapy | Hypertension - chemically induced | Camptothecin - administration & dosage | Leucovorin - therapeutic use | 3' Untranslated Regions | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Glycine Hydroxymethyltransferase - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Genetic Association Studies | Homocysteine - blood | Treatment Outcome | Dihydrouracil Dehydrogenase (NADP) - blood | Thymidylate Synthase - genetics | Polymorphism, Genetic | Disease-Free Survival | 5' Untranslated Regions | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Creatinine - blood | Colorectal Neoplasms - secondary | Index Medicus
Journal Article
日本臨床外科学会雑誌, ISSN 1345-2843, 2015, Volume 76, Issue 8, pp. 1980 - 1984
症例は73歳の男性,主訴は排便困難感.精査にて膀胱結腸瘻を伴う直腸S状部癌,cT4N0M0 cStage... 
術前化学療法 | 膀胱浸潤 | FOLFIRI+Bevacizumab療法
Journal Article
YAKUGAKU ZASSHI, ISSN 0031-6903, 2018, Volume 138, Issue 1, pp. 83 - 90
Journal Article
YAKUGAKU ZASSHI, ISSN 0031-6903, 2011, Volume 131, Issue 8, pp. 1251 - 1257
Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) for treatment of metastatic colorectal cancer. Recently, much... 
bevacizumab | colorectal cancer | hypertension | mFOLFOX6 | predictive factor | FOLFIRI
Journal Article
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, ISSN 0031-6903, 08/2011, Volume 131, Issue 8, pp. 1251 - 1257
Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) for treatment of metastatic colorectal cancer. Recently, much... 
1ST-LINE TREATMENT | CONTROLLED-TRIAL | colorectal cancer | PLUS IRINOTECAN | PHASE-III | OXALIPLATIN | FLUOROURACIL | FACTOR RECEPTOR | mFOLFOX6 | FOLFIRI | predictive factor | bevacizumab | ORAL FLUOROPYRIMIDINES | BICC-C | PHARMACOLOGY & PHARMACY | hypertension | ENDOTHELIAL GROWTH-FACTOR | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Molecular Targeted Therapy | Bevacizumab | Colorectal Neoplasms - etiology | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacology | Colorectal Neoplasms - drug therapy | Hypertension - chemically induced | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Blood Pressure - drug effects | Retrospective Studies | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Angiogenesis Inhibitors - pharmacology | Treatment Outcome | Vascular Endothelial Growth Factor A - immunology | Forecasting | Disease-Free Survival | Asian Continental Ancestry Group | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Index Medicus
Journal Article
医療薬学, ISSN 1346-342X, 2009, Volume 35, Issue 5, pp. 337 - 342
The aim of this study was to clarify the influence of renin-angiotensin (RA) system blockers on the anti-cancer effect of chemotherapy with bevacizumab and its... 
renin-angiotensin system blockers | bevacizumab | anti-cancer effect | hypertension | mFOLFOX 6 | FOLFIRI
Journal Article
長崎醫學會雜誌 : Nagasaki Igakkai zasshi, ISSN 0369-3228, 06/2009, Volume 84, pp. 1 - 5
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.